2622-26-6
2622-26-6
Chemical Structure
Pericyazine
Synonym(s): Propericiazine; RP 8909
- CAS No.: 2622-26-6
- Formula:C21H23N3OS
- Molecular Weight:365.49
IUPAC Name: 10-(3-(4-hydroxypiperidin-1-yl)propyl)-10H-phenothiazine-2-carbonitrile
InChIKey: LUALIOATIOESLM-UHFFFAOYSA-N
SMILES: N#CC(C=C1N2CCCN3CCC(O)CC3)=CC=C1SC4=C2C=CC=C4
Biological Activity: Pericyazine (Propericiazine) is a first-generation antipsychotic agent that is used as an adjunct to the short-term management of severe anxiety states and psychosis[1]. Pericyazine is a selective D2-dopamine receptor antagonist[2][3]. Pericyazine has adrenolytic, anticholinergic, and extrapyramidal effects[4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pericyazine | 99.86% | Pericyazine (Propericiazine) is a first-generation antipsychotic agent that is used as an adjunct to the short-term management of severe anxiety states and psychosis. Pericyazine is a selective D2-dopamine receptor antagonist. Pericyazine has adrenolytic, anticholinergic, and extrapyramidal effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pericyazine (Standard) | ≥98% | Pericyazine (Standard) is the analytical standard of Pericyazine. This product is intended for research and analytical applications. Pericyazine (Propericiazine) is a first-generation antipsychotic agent that is used as an adjunct to the short-term management of severe anxiety states and psychosis. Pericyazine is a selective D2-dopamine receptor antagonist. Pericyazine has adrenolytic, anticholinergic, and extrapyramidal effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Morley KC, et al. Pericyazine in the treatment of cannabis dependence in general practice: a naturalistic pilot trial. Subst Abuse Rehabil. 2012 May 28;3:43-7. [Content Brief]
- [2]. Farde L, et al. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypicalneuroleptics. Psychopharmacology (Berl). 1989;99 Suppl:S28-31. [Content Brief]
- [3]. Divac N, et al. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370. [Content Brief]
- [4]. Cai HL, et al. A sensitive LC-MS/MS method for analysis of pericyazine in presence of 7-hydroxypericyazine and pericyazine sulphoxide in human plasma and its application to a comparative bioequivalence study in Chinese healthy volunteers. J Pharm Biomed Anal. 2017;135:67‐74. [Content Brief]
